Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by deeppocket83on Oct 31, 2016 6:21pm
200 Views
Post# 25407842

Valeant - News Release (BS Rumours)

Valeant - News Release (BS Rumours)https://web.tmxmoney.com/article.php?newsid=6115204958507558&qm_symbol=VRX

LAVAL, Quebec, Oct. 31, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today issued the following statement regarding comments attributed to anonymous sources in a press report regarding the ongoing investigation being conducted by the U.S. Attorney's Office for the Southern District of New York:

"As Valeant previously stated in response to a prior, similar press report, the Company previously disclosed in October 2015 that the United States Attorney's Office for the Southern District of New York commenced an investigation involving Valeant.We have been fully cooperating with the authorities throughout the investigation, and we are in frequent contact and continue to cooperate with the U.S. Attorney's Office for the Southern District of New York. We do not comment on rumors about investigations, and cannot comment on or speculate about the possible course of any ongoing investigation.

"Valeant takes these matters seriously and intends to uphold the highest standards of ethical conduct as we move forward with our mission to improve people's lives with our healthcare products."

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Elif McDonald

514-856-3855
877-281-6642 (toll free)

Media:
Rene Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

Valeant Pharmaceuticals International, Inc.

Logo - https://photos.prnewswire.com/prnh/20101025/LA87217LOGO

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/valeant-pharmaceuticals-comments-on-press-report-300354317.html

SOURCE Valeant Pharmaceuticals International, Inc.


<< Previous
Bullboard Posts
Next >>